Impaired cornea wound healing in a tenascin C-deficient mouse model

Laboratory Investigation

Volumn 93, Issue 2, 2013, Pages 207-217

  Sumioka, Takayoshi ^a   Kitano, Ai ^a   Flanders, Kathleen C ^b   Okada, Yuka ^a   Yamanaka, Osamu ^a   Fujita, Norihito ^a   Iwanishi, Hiroki ^a   Kao, Winston W Y ^c   Saika, Shizuya ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

cell culture; cornea; mouse; myofibroblast; tenascin C; transforming growth factor b; wound healing

Indexed keywords

COLLAGEN I ALPHA 1; COLLAGEN TYPE 1; EOSIN; FIBRONECTIN; HEMATOXYLIN; MESSENGER RNA; TENASCIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INVASION; CONTROLLED STUDY; CORNEA INJURY; FIBROBLAST; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INCISION; KNOCKOUT MOUSE; MACROPHAGE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; QUALITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA; UPREGULATION; WILD TYPE; WOUND CLOSURE; WOUND HEALING;

ANALYSIS OF VARIANCE; ANIMALS; COLLAGEN TYPE I; CORNEA; CORNEAL STROMA; FIBRONECTINS; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TENASCIN; TRANSFORMING GROWTH FACTOR BETA1; WOUND HEALING;

EID: 84873867601     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.157     Document Type: Article

References (37)

1. Brodovsky SC, McCarty CA, Snibson G, et al. Management of alkali burns: an 11-year retrospective review. Ophthalmology 2000;107: 1829-1835.
2. Meller D, Pires RT, Mack RJ, et al. Amniotic membrane transplantation for acute chemical or thermal burns. Ophthalmology 2000;107: 980-989.
3. Ishizaki M, Zhu G, Haseba T, et al. Expression of collagen I, smooth muscle a-actin, and vimentin during the healing of alkali-burned and lacerated corneas. Invest Ophthalmol Vis Sci 1993;34:3320-3328.
4. Saika S, Kobata S, Hashizume N, et al. Epithelial basement membrane in alkali-burned corneas in rats. Immunohistochemical study. Cornea 1993;12:383-390.
5. Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechanoregulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002;3:349-363.
6. Saika S, Ikeda K, Yamanaka O, et al. Expression of Smad7 in mouse eyes accelerates healing of corneal tissue after exposure to alkali. Am J Pathol 2005;166:1405-1418.
7. Saika S, Miyamoto T, Yamanaka O, et al. Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factor-kappaB, in treatment of corneal alkali burns in mice. Am J Pathol 2005;166: 1393-1403.
8. Saika S. TGFb pathobiology in the eye. Lab Invest 2006;86:106-115.
9. Chiquet-Ehrismann R. Tenascins. Int J Biochem Cell Biol 2004;36: 986-990.
10. Tucker RP, Chiquet-Ehrismann R. The regulation of tenascin expression by tissue microenvironments. Biochim Biophys Acta 2008;1793: 888-992.
11. Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal 2009;3:287-310.
12. Shrestha P, Sakamoto F, Takagi H, et al. Enhanced tenascin immunoreactivity in leukoplakia and squamous cell carcinoma of the oral cavity: an immunohistochemical study. Eur J Cancer B Oral Oncol 1994;30:132-137.
13. El-Karef A, Yoshida T, Gabazza EC, et al. Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J Pathol 2007;211:86-94.
14. Maseruka H, Bonshek RE, Tullo AB. Tenascin-C expression in normal, inflamed, and scarred human corneas. Br J Ophthalmol 1997;81: 677-682.
15. Maseruka H, Ridgway A, Tullo A, et al. Developmental changes in patterns of expression of tenascin-C variants in the human cornea. Invest Ophthalmol Vis Sci 2000;41:4101-4107.
16. Matsuda A, Yoshiki A, Tagawa Y, et al. Corneal wound healing in tenascin knockout mouse. Invest Ophthalmol Vis Sci 1999;40: 1071-1080.
17. Saika S, Ikeda K, Yamanaka O, et al. Loss of tumor necrosis factor a potentiates transforming growth factor b-mediated pathogenic tissue response during wound healing. Am J Pathol 2006;168:1848-1860.
18. Saika S, Ikeda K, Yamanaka O, et al. Adenoviral gene transfer of BMP-7, Id2, or Id3 suppresses injury-induced epithelial-to-mesenchymal transition of lens epithelium in mice. Am J Physiol Cell Physiol 2006; 290:282-289.
19. Fattman CL, Gambelli F, Hoyle G, et al. Epithelial expression of TIMP-1 does not alter sensitivity to bleomycin-induced lung injury in C57BL/6 mice. Am J Physiol Lung Cell Mol Physiol 2008;294:L572-L581.
20. Saika S, Yamanaka O, Sumioka T, et al. Fibrotic disorders in the eye: targets of gene therapy. Prog Retin Eye Res 2008;27:177-196.
21. Sumioka T, Fujita N, Kitano A, et al. Impaired angiogenic response in the cornea of mice lacking tenascin C. Invest Ophthalmol Vis Sci 2011;52:2462-2467.
22. Forsberg E, Hirsch E, Frö hlich L, et al. Skin wounds and severed nerves heal normally in mice lacking tenascin-C. Proc Natl Acad Sci USA 1996;93:6594-6599.
23. Sta Iglesia DD, Gala PH, Qiu T, et al. Integrin expression during epithelial migration and restratification in the tenascin-C-deficient mouse cornea. J Histochem Cytochem 2000;48:363-376.
24. Miyazaki K, Okada Y, Yamanaka O, et al. Corneal wound healing in an osteopontin-deficient mouse. Invest Ophthalmol Vis Sci 2008;49: 1367-1375.
25. Fujita N, Fujita S, Okada Y, et al. Impaired angiogenic response in the corneas of mice lacking osteopontin. Invest Ophthalmol Vis Sci 2010;51:790-794.
26. Ballard VL, Sharma A, Duignan I, et al. Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization. FASEB J 2006;20:717-719.
27. Ishiwata T, Takahashi K, Shimanuki Y, et al. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res 2005;25:489-495.
28. Saito Y, Shiota Y, Nishisaka M, et al. Inhibition of angiogenesis by a tenascin-c peptide which is capable of activating b1-integrins. Biol Pharm Bull 2008;31:1003-1007.
29. Wallner K, Li C, Shah PK, et al. Tenascin-C is expressed in macrophagerich human coronary atherosclerotic plaque. Circulation 1999;99: 1284-1289.
30. Carey WA, Taylor GD, Dean WB, et al. Tenascin-C deficiency attenuates TGF-b-mediated fibrosis following murine lung injury. Am J Physiol Lung Cell Mol Physiol 2010;299:L785-L793.
31. Garamszegi N, Garamszegi SP, Samavarchi-Tehrani P, et al. Extracellular matrix-induced transforming growth factor-b receptor signaling dynamics. Oncogene 2010;29:2368-2380.
32. Margadant C, Sonnenberg A. Integrin-TGF-b crosstalk in fibrosis, cancer and wound healing. EMBO Rep 2010;11:97-105.
33. Bhowmick NA, Zent R, Ghiassi M, et al. Integrin b1 signaling is necessary for transforming growth factor-b activation of p38MAPK and epithelial plasticity. J Biol Chem 2001;276:46707-46713.
34. Lamar JM, Iyer V, DiPersio CM. Integrin a3b1 potentiates TGFbmediated induction of MMP-9 in immortalized keratinocytes. J Invest Dermatol 2008;128:575-586.
35. Scaffidi AK, Petrovic N, Moodley YP, et al. a(v)b(3) Integrin interacts with the transforming growth factor b (TGFb) type II receptor to potentiate the proliferative effects of TGFb1 in living human lung fibroblasts. J Biol Chem 2004;279:37726-37733.
36. Galliher AJ, Schiemann WP. b3 integrin and Src facilitate transforming growth factor-b mediated induction of epithelialmesenchymal transition in mammary epithelial cells. Breast Cancer 2006;8:R42.
37. Asano Y, Ihn H, Yamane K, et al. Increased expression of integrin avb5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 2006;168:499-510.